Global Oncolytic Virus Therapy Market was estimated at US$ 103.19 million and is projected to rise CAGR of 25.10% from 2021-2027 to cross US$ 514.36 million by 2027. Oncolytic Virus Therapy Market is one of the most promising and effective virus therapeutics for cancer patients. The virus infects and breaks down the cancer cell in an OV therapy treatment, making it easier for other medicines like chemotherapy to work. Because OV medicines are directly injected into the tumour region, it is also termed as targeted therapy. The market for OV treatment is still in its early stages, with clinical trials underway to see if it can be used to treat a variety of tumours. Melanoma cancer, breast cancer, prostate cancer, and a few other cancer treatments have all been successful. The oncolytic viral therapy market is being driven by the increasing use of target therapy over traditional therapy, the emergence of biosimilars, increased demand for mAbs, and the rising prevalence of cancer. The market is projected to be driven by successful clinical trials and the successful combination of oncolytic viral therapy with chemotherapeutic drugs. Market expansion will be aided by recent technological improvements in cancer treatments and the development of new therapeutics. Oncology encompasses more than 20 different indications, yet only five of them account for the majority of income. Breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-lymphoma Hodgkin’s (NHL) will account for around 65% of the market by 2020. These five have high rates of occurrence and unmet needs. Brain, head, and neck cancers, skin cancers, thyroid cancers, pancreas cancers, bladder cancers, kidney and renal pelvis cancers, and soft tissue cancers are all frequent. Breast, lung, colon, and rectum cancers are the three most frequent cancers in women, and they are predicted to account for half of all new cancer diagnoses by 2026. According to the statistics, oncolytic viral therapy has a lot of room to grow in the cancer sector in the near future. In February 2019, Mustang Bio and National Children’s Hospital signed an exclusive worldwide license agreement to produce an oncolytic virus (c134) for treating Glioblastoma Multiforme. In February 2019, Cytonus Therapeutics Inc. revealed that it has created Cargocytes a first-of-its-kind, controllable, cell-based biologic delivery platform technology. In February 2019, Oncolytics Biotech Inc. is currently developing pelareorep, announced that it has been given final approval by the Spanish Department for Medicine and Health Products for the upcoming AWARE-1 breast cancer opportunities research.